Juniper Pharmaceuticals (NASDAQ: JNP) and Corium International (NASDAQ:CORI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Juniper Pharmaceuticals and Corium International, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juniper Pharmaceuticals 0 1 2 0 2.67
Corium International 0 0 7 0 3.00

Juniper Pharmaceuticals presently has a consensus price target of $23.00, indicating a potential upside of 350.98%. Corium International has a consensus price target of $13.17, indicating a potential upside of 17.35%. Given Juniper Pharmaceuticals’ higher probable upside, analysts plainly believe Juniper Pharmaceuticals is more favorable than Corium International.

Risk and Volatility

Juniper Pharmaceuticals has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Corium International has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Profitability

This table compares Juniper Pharmaceuticals and Corium International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juniper Pharmaceuticals 10.80% 17.32% 11.65%
Corium International -149.99% -612.73% -64.69%

Earnings and Valuation

This table compares Juniper Pharmaceuticals and Corium International’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Juniper Pharmaceuticals $54.57 million 1.01 $5.95 million $0.59 8.64
Corium International $31.86 million 12.68 -$47.79 million ($1.67) -6.72

Juniper Pharmaceuticals has higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than Juniper Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

36.4% of Juniper Pharmaceuticals shares are held by institutional investors. Comparatively, 89.4% of Corium International shares are held by institutional investors. 7.2% of Juniper Pharmaceuticals shares are held by company insiders. Comparatively, 45.7% of Corium International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Juniper Pharmaceuticals beats Corium International on 7 of the 13 factors compared between the two stocks.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

About Corium International

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Juniper Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.